Proove Genomics Relaunches to Revolutionize Pain Management and Combat Opioid Crisis
Health Technology Executive and Award-Winning Social Entrepreneur Brian Meshkin relaunches Proove Genomics with a renewed mission to provide personalized and predictive pain management solutions. Backed by the world’s largest clinical-genetic data bank for pain and orthopedics, Proove Genomics utilizes advanced genetic and IT tools to move beyond subjective pain assessments and improve treatment outcomes. Proove Genomics leads the fight against chronic pain and opioid addiction in the U.S., addressing both crises that affect millions. Their lab testing evaluates genetic and phenotypic factors to assess pain sensitivity, opioid use disorder risk, and effective treatment options. With evidence from over 13,000 patients showing significant reductions in pain and opioid use disorder, Proove Genomics is a trusted leader in personalized medicine for pain management. “Patients deserve to be understood individually to improve their quality of life,” says Meshkin. “Our team is committed to this mission and the comeback story for pain patients and their clinicians.”
Proove Genomics Relaunches to Revolutionize Pain Management and Combat Opioid Crisis